United States Patent 10,023,917: Claims and Patent Landscape Analysis
What are the core claims of Patent 10,023,917?
Patent 10,023,917 (hereinafter referred to as the '917 patent) primarily claims a novel method for the targeted delivery of therapeutic agents using engineered nanocarriers. The patent describes specific compositions involving lipid-based nanoparticles with surface modifications designed to enhance cellular uptake and specificity for cancer cells. The key claims include:
-
Claim 1: A composition comprising lipid nanoparticles with surface-conjugated targeting ligands specific to cancer cell biomarkers.
-
Claim 2: The lipid nanoparticles consist of a lipid bilayer core encapsulating a therapeutic agent, such as a chemotherapeutic drug.
-
Claim 3: The surface-conjugated targeting ligands include antibodies or antibody fragments specific to tumor-associated antigens.
-
Claim 4: The nanoparticle size ranges between 50 nm and 150 nm for optimal tumor penetration.
-
Claim 5: A method of treating cancer by administering the described nanoparticle composition.
Claims extend to specific lipid compositions, preparation methods, and use cases for delivering siRNA or small-molecule drugs. The patent emphasizes enhanced targeting efficiency and reduced systemic toxicity.
How do the claims stand in relation to prior art?
The claims build upon existing lipid nanoparticle technologies like Doxil and Onpattro but introduce specific surface modifications—particularly conjugation with monoclonal antibodies—to improve targeting precision. The patent differentiates itself from prior art through:
-
Size optimization: Claiming a narrower nanoparticle size range (50–150 nm) compared to broader ranges in prior art.
-
Targeting ligands: Using specific antibody fragments that recognize distinct tumor antigens (e.g., HER2, EGFR).
-
Preparation process: The patent discloses a method involving controlled conjugation chemistry that ensures stability of surface ligands during storage.
The patent's novelty claim hinges on the combination of these features rather than any single element, which can complicate validity arguments if prior art discloses similar compositions or methods.
What is the patent landscape surrounding this innovation?
The landscape includes the following categories of patents:
| Category |
Key Patents / Publications |
Date Range |
Notes |
| Lipid nanoparticle delivery |
US Patent 9,695,665 (mRNA lipid formulations), EP 3,345,957 (targeted delivery) |
2017–2020 |
Focuses on lipid composition and encapsulation techniques |
| Surface modification and targeting |
US Patent 8,543,927 (antibody conjugation to nanoparticles), WO2016159913 |
2014–2016 |
Explores conjugation chemistries for antibody attachment |
| Specific targeting in vivo |
US Patent 10,128,563 (tumor targeting with conjugated nanoparticles) |
2018 |
Describes targeting nanoparticle systems for solid tumors |
This landscape demonstrates active R&D within targeted nanomedicine, with many patents focusing on antibody conjugation and lipid formulations. The '917 patent combines these elements but with specific claims around nanoparticle size and composition.
Crucially, the primary prior art references the use of lipid nanoparticles with surface-bound targeting agents, which could challenge the novelty of Claim 1. The patent's inventiveness may require demonstrating technical differences in conjugation stability, or size control, to withstand validity challenges.
Are there potential infringement issues?
Potential infringement could occur where a nanoparticle formulation incorporates:
-
Lipid-based carriers in the claimed size range (50–150 nm).
-
Surface-conjugated tumor-specific antibodies or fragments.
-
Encapsulation of therapeutic agents, including siRNA or chemotherapeutics.
Key players in the space, such as Moderna, BioNTech, and Acuitas, all develop lipid nanoparticle platforms that may overlap with these claims, especially if their formulations include antibody conjugates. The scope of Claims 1–3 appears broad enough to ensnare several commercial products under development or already marketed.
How does regulatory and licensing activity influence this landscape?
The growth in this field correlates with regulatory approvals for mRNA vaccines (e.g., Moderna's Spikevax). Patents like the '917 patent can act as blocking patents for follow-on formulations or derivatives.
Licensing agreements have emerged, with companies such as Moderna and Arbutus signing cross-licensing deals related to lipid nanoparticle technology. The '917 patent's enforceability could influence licensing negotiations or settlement strategies, particularly given its focus on well-validated delivery platforms.
What are the potential opportunities and risks?
Opportunities:
-
Use of the '917 patent claims as a foundation for advanced targeted therapeutics in oncology.
-
Partnership with patent holders to develop next-generation nanoparticle systems.
-
Licensing of the patent to expand technology portfolios.
Risks:
-
Patent invalidity due to prior art combinations, challenging the claims' novelty.
-
Narrow claim scope limiting broad application.
-
Litigation costs if patent assertion leads to enforcement actions.
Key Takeaways
-
The '917 patent claims a targeted lipid nanoparticle delivery system with specific size and surface modification features.
-
It builds upon prior art related to lipid formulations and antibody conjugation but seeks to combine features in ways that may confer novelty.
-
The patent landscape is crowded but still evolving, with active patenting around lipid compositions and targeting ligands.
-
Infringement could occur in current and pipeline therapeutics that utilize lipid nanoparticles with antibody conjugates within the claimed parameters.
-
Its enforceability and strategic value depend on rigorous validity assessment and potential licensing opportunities.
FAQs
1. Does the '917 patent cover all targeted lipid nanoparticles?
No. It covers specific compositions with particular size ranges and surface conjugates. Broader targeted nanoparticle systems may fall outside its claims.
2. Can existing lipid nanoparticle drugs infringe this patent?
Possibly, if they include the claimed features—size, surface conjugation, and encapsulated agents—within the patent’s scope.
3. Is the patent likely to withstand validity challenges?
The combination of features may face objections based on prior art, especially regarding the uniqueness of conjugation methods and size specification.
4. How does the patent impact future nanomedicine development?
It provides a patent estate around targeted lipid nanoparticles that could enable licensing opportunities but also creates potential barriers for generic or alternative approaches.
5. What should patent applicants consider when designing similar delivery systems?
They should carefully evaluate claim scope, avoid overlapping features, and innovate in ligand chemistry, nanoparticle size control, or formulation stability to maintain patentability.
References
- U.S. Patent and Trademark Office (USPTO). Patent No. 10,023,917.
- Smith, J. A., & Johnson, L. M. (2020). Advances in targeted lipid nanoparticle delivery systems. Journal of Nanomedicine & Nanotechnology, 11(3), 123-135.
- Zhang, Y., et al. (2019). Surface chemistry and stability of antibody-conjugated lipid nanoparticles. Nanomedicine: Nanotechnology, Biology, and Medicine, 15, 72–80.
- European Patent Office (EPO). Patent No. 3,345,957.
- World Intellectual Property Organization (WIPO). WO 2016/159913.
